Nemaura Medical Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Nemaura Medical Inc (NMRD) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
API endpoints for this dataset
Nemaura Medical Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Nemaura Medical Inc | - | - | - | Yes |
| Competitors combined (15) | ||||
| High-Confidence Competitors (6) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
NMRD Stock Performance relative to its Competitors
NMRD Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Senseonics Holdings Inc | 282.9% | Outperformed |
| 2 | Dexcom Inc | 282.9% | Outperformed |
| 3 | Tandem Diabetes Care Inc | 282.9% | Outperformed |
| 4 | Medtronic Plc | 282.9% | Outperformed |
| 5 | Abbott Laboratories | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Nemaura Medical Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Nemaura Medical Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Nemaura Medical Inc |
0.00 | - |
 Abbott Laboratories |
188,597.56 | 48,229.00 |
 Medtronic Plc |
132,185.39 | 37,542.00 |
 Dexcom Inc |
31,957.06 | 5,104.90 |
 Modular Medical Inc |
10,740.44 | - |
 Insulet Corporation |
10,582.57 | 3,053.40 |
| SUBTOTAL | 376,905.22 | 96,080.20 |
Sign in to see all competitors of Nemaura Medical Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Nemaura Medical Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Nemaura Medical Inc's Competitors Named by the Company
Competitive relationships identified from Nemaura Medical Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Usbc Inc | Company report | 85% |
| Movano Inc | Company report | 85% |
| Northview Acquisition Corp | Company report | 85% |
| KNW | Company report | 85% |
| Abbott | Company report | 85% |
| Dexcom | Company report | 85% |
| Senseonics | Company report | 85% |
| Dariohealth Corp | Company report | 85% |
| Glucotrack Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Nemaura Medical Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Nemaura Medical Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Abbott Laboratories | Diabetes Care 16.79 % |
| Medtronic Plc | CARDIOVASCULAR 38.34 % |
| Dexcom Inc | Reportable 100.00 % |
| Movano Inc | AI Platform and Services 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Nemaura Medical Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Nemaura Medical Inc | 0 | - | -343,578 |
| Abbott Laboratories | 188,598 | 419,383 | 40,878 |
| Medtronic Plc | 132,185 | 395,179 | 55,463 |
| Dexcom Inc | 31,957 | 459,901 | 89,432 |
| Modular Medical Inc | 10,740 | - | -549,529 |
| Insulet Corporation | 10,583 | 565,444 | 69,500 |
| PEERS TOTAL | 376,905 | 415,182 | 82,475 |
Sign in to see all peers for Nemaura Medical Inc .
Nemaura Medical Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Abbott Laboratories | Non-US 57.70 % |
| Medtronic Plc | United States 49.83 % |
| Dexcom Inc | United States 72.13 % |
| Insulet Corporation | United States 68.40 % |
| Tandem Diabetes Care Inc | United States 67.34 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Nemaura Medical Inc .
Nemaura Medical Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 218 companies in Nemaura Medical Inc's industry classification, broader than the peer set above. Market cap in millions of $.Nemaura Medical Inc ranks #0 of 218 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 598, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Intuitive Surgical Inc | 158,495 | 13.15 % |
| 2 | Medtronic Plc | 132,185 | 10.97 % |
| 3 | Stryker Corp | 119,521 | 9.91 % |
| 4 | 3m Company | 95,944 | 7.96 % |
| 5 | Boston Scientific Corporation | 1,234 | 5.2% |
| 6 | Edwards Lifesciences Corporation | 1,234 | 5.2% |
| 7 | Becton Dickinson And Company | 1,234 | 5.2% |
| 8 | Alcon inc | 1,234 | 5.2% |
| 9 | Resmed Inc | 1,234 | 5.2% |
| 10 | Medline Inc | 1,234 | 5.2% |
| 0 | Nemaura Medical Inc | - | 0.00 % |
Market cap and industry share for the rest of Nemaura Medical Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-12.
Nemaura Medical Inc's Valuation vs Competitive Position
Valuation multiples vs the Medical Equipment & Supplies industry average (341 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Medical Equipment & Supplies industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 37.0x | - |
| EV / EBITDA | - | 17.4x | - |
| P/B | -0.5x | 4.6x | -5.1x |
| Return on Equity | - | industry aggregate | - |
| Return on Invested Capital | - | -6.54 % (avg) | - |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Nemaura Medical Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - |
| Operating Margin | - | - | - | - | - |
| Return on Invested Capital | -169.98 % | -32.59 % | -26.26 % | - | - |
| P/E | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Nemaura Medical Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 598 (see Industry Market Structure & Concentration above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Nemaura Medical Inc's dedicated Suppliers and Customers pages, not here.
Nemaura Medical Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of competitors (46.70 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-15.2% annualized).
Methodology: see Methodology: SWOT Analysis.
Nemaura Medical Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Nemaura Medical Inc | 0.13 | 0.38 | - |
| Abbott Laboratories | 0.36 | 1.45 | 0.53 |
| Medtronic Plc | 0.15 | 2.10 | 0.57 |
| Dexcom Inc | 0.46 | 1.82 | 0.46 |
| Modular Medical Inc | 3.38 | 3.67 | - |
| Insulet Corporation | - | 2.66 | 0.86 |
Sign in to see all peers for Nemaura Medical Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Nemaura Medical Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Nemaura Medical Inc | Q4 2023 | - | - |
| Abbott Laboratories | Q3 2026 | +14.5 % | -44.0 % |
| Medtronic Plc | Q2 2026 | +13.7 % | +41.3 % |
| Dexcom Inc | Q3 2026 | +11.3 % | -3.1 % |
| Modular Medical Inc | Q2 2026 | - | - |
| Insulet Corporation | Q2 2026 | +23.5 % | +322.2 % |
| PEERS TOTAL | +13.9 % | +257.3 % |
Sign in to see all peers for Nemaura Medical Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Nemaura Medical Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Nemaura Medical Inc | Q4 2023 | - | -81.9 % |
| Abbott Laboratories | Q3 2026 | +10.9 % | +3.4 % |
| Medtronic Plc | Q2 2026 | +13.8 % | -0.2 % |
| Dexcom Inc | Q3 2026 | +0.6 % | -34.3 % |
| Modular Medical Inc | Q2 2026 | - | -26.3 % |
| Insulet Corporation | Q2 2026 | +21.4 % | +60.8 % |
Sign in to see all peers for Nemaura Medical Inc .
Nemaura Medical Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Nemaura Medical Inc | - | - | - |
| Abbott Laboratories | 4.54% | 5.14% | 9.00% |
| Medtronic Plc | 5.71% | 6.46% | 10.64% |
| Dexcom Inc | 15.47% | 18.92% | 36.56% |
| Modular Medical Inc | - | - | - |
| Insulet Corporation | 12.13% | 14.30% | 26.69% |
Sign in to see all peers for Nemaura Medical Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Nemaura Medical Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Nemaura Medical Inc | - | - |
| Abbott Laboratories | 40.19 | 3.91 |
| Medtronic Plc | 302.53 | 3.52 |
| Dexcom Inc | 32.81 | 6.26 |
| Modular Medical Inc | - | - |
| Insulet Corporation | 28.55 | 3.47 |
| PEERS AVERAGE | 19.76 | 3.92 |
Sign in to see all peers for Nemaura Medical Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.